James O.

James O. has extensive work experience in the field of medicinal chemistry. James is currently employed as the Senior Director and Head of Chemistry at Adrestia Therapeutics, a position they have held since October 2022. Prior to this, James was the Director of Medicinal Chemistry at Amphista Therapeutics Limited from July 2021 to October 2022, and at GW Pharmaceuticals plc from March 2020 to July 2021. James also served as the Associate Director of Medicinal Chemistry at Astex Pharmaceuticals (UK) from June 2018 to March 2020.

Before joining Astex Pharmaceuticals, James held various roles at Charles River Laboratories, starting as a Team Leader in January 2014 and working there until June 2018. James also worked at BioFocus as a Senior Scientist from April 2012 to January 2014, and as a Scientist from September 2011 to March 2012.

James began their career as a Medicinal Chemist at ICR in February 2009 and worked there until August 2011. James completed their post-doctoral research at Oxford University from January 2006 to January 2009. During this time, they worked on Rh-catalysed hydroacylation and Buchwald-Hartwig aminations, developing and optimizing asymmetric rhodium intermolecular hydroacylation and establishing a novel chemoselective rhodium-catalysed reductive aldol or hydroacylation system.

James O. obtained their PhD in Chemistry from the University of Nottingham. James attended the university from 2002 to 2005 and successfully completed their doctoral degree in Chemistry during this time.